Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - AVADEL PHARMACEUTICALS PLC | avdlex-312.htm |
| EX-32.2 - EXHIBIT 32.2 - AVADEL PHARMACEUTICALS PLC | avdlex-322.htm |
| EX-32.1 - EXHIBIT 32.1 - AVADEL PHARMACEUTICALS PLC | avdlex-321.htm |
| EX-31.1 - EXHIBIT 31.1 - AVADEL PHARMACEUTICALS PLC | avdlex-311.htm |
| EX-23.1 - EXHIBIT 23.1 - AVADEL PHARMACEUTICALS PLC | avdlex-231.htm |
| EX-21.1 - EXHIBIT 21.1 - AVADEL PHARMACEUTICALS PLC | avdlex-211.htm |
| EX-10.32 - EXHIBIT 10.32 - AVADEL PHARMACEUTICALS PLC | avdlex-1032.htm |
| EX-10.31 - EXHIBIT 10.31 - AVADEL PHARMACEUTICALS PLC | avdlex-1031.htm |
| EX-4.1 - EXHIBIT 4.1 - AVADEL PHARMACEUTICALS PLC | avdlex-41.htm |
| 10-K - FORM 10-K - AVADEL PHARMACEUTICALS PLC | avdl201610k.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No.’s 333-213154, 333-212585 and 333-177591 on Form S-8 and No. 333-183961 on Form S-3 of our report dated March 28, 2017, relating to the 2016 consolidated financial statements and 2016 financial statement schedule of Avadel Pharmaceuticals PLC (the “Company”) and the effectiveness of the Company's internal control over financial reporting (which internal control report expresses an adverse opinion on the Company’s internal control over financial reporting because of material weaknesses), appearing in the Annual Report on Form 10-K of Avadel Pharmaceuticals PLC for the year ended December 31, 2016.
/s/ Deloitte and Touche LLP
St. Louis, Missouri
March 28, 2017